Online inquiry

IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11707MR)

This product GTTS-WQ11707MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11707MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3894MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ9474MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ1290MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ9986MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ7399MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ4226MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ8125MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ13683MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW